<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109269">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01911364</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1208-PR-0090</org_study_id>
    <nct_id>NCT01911364</nct_id>
  </id_info>
  <brief_title>Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the triple combination of beclometasone
      dipropionate+Formoterol fumarate+Glycopyrrolate bromide is effective for the treatment of
      severe COPD patients (chronic obstructive pulmonary disease)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 52-WEEK, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, 3-ARM PARALLEL GROUP, ACTIVE CONTROLLED
      CLINICAL TRIAL OF FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE
      PLUS GLYCOPYRROLATE BROMIDE ADMINISTERED VIA PMDI (CHF 5993) VERSUS TIOTROPIUM BROMIDE AND
      VERSUS FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE ADMINISTERED
      VIA PMDI AND TIOTROPIUM BROMIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

      A total of 8 clinic visits (V0 to V7) will be performed during the study, as follows:

        -  A pre-screening visit (V0) to obtain the written informed consent from the patient

        -  A screening visit (V1) to establish the eligibility of patients, followed by a 2-week
           open-label run-in under Tiotropium

        -  After the randomisation (V2), patients will be assessed after 4, 12, 26, 40 and 52
           weeks of treatment (V3 to V7) The assessments performed at visits include routine
           haematology and blood chemistry, medical history, physical examination, a 12-lead ECG,
           spirometric parameters, vital signs).

      During the run-in and the randomised treatment periods, patients use an e-diary to record
      symptoms, rescue medication use and compliance to the study medications daily.

      AEs/SAEs and COPD exacerbations will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>COPD exacerbation rate</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Moderate and severe COPD exacerbation rate over 52 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pre-dose morning FEV1</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in pre-dose morning FEV1 at Week 52.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3686</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>BDP/FF/GB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium bromide 18 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP/FF + Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily
BDP/FF/GB versus BDP/FF + Tiotropium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP/FF/GB</intervention_name>
    <arm_group_label>BDP/FF/GB</arm_group_label>
    <other_name>CHF 5993 pMDI 100/6/12.5 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Spiriva 18 mcg 1 capsule o.d</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP/FF + Tiotropium</intervention_name>
    <arm_group_label>BDP/FF + Tiotropium</arm_group_label>
    <other_name>Foster 100/6 mcg 2 inhalations bid + Spiriva 18 mcg o.d.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female COPD patients aged ≥ 40 years

          -  Current smokers or ex-smokers

          -  FEV1&lt;50% predicted (FEV1/FVC &lt;0,7)

          -  at least 1 documented exacerbations in the last 12 Mo

        Exclusion Criteria:

          -  Pregnant or lactating women and all women physiologically capable of becoming
             pregnant

          -  Diagnosis of asthma, history of allergic rhinitis or atopy

          -  Patients treated for exacerbations 1 Mo prior to screening

          -  Patients treated with non-cardioselective β-blockers

          -  Patients treated with long-acting antihistamines

          -  Known respiratory disorders other than COPD

          -  Patients who have clinically significant cardiovascular condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorgen Vestbo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Respiratory Research Group, Wythenshawe Hospital, MANCHESTER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Petruzzelli, MD, Prof</last_name>
    <phone>+390521279744</phone>
    <email>s.petruzzelli@chiesi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geraldine Cohuet</last_name>
    <phone>+33147684146</phone>
    <email>g.cohuet@chiesi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut für klinische Forschung</name>
      <address>
        <city>Hesse</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabine Ballenberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Csongrád Megyei Mellkasi Betegségek Szakkórháza</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beatrix Balint</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maurizio Dottorini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Frequent exacerbators</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Formoterol</mesh_term>
    <mesh_term>Tiotropium</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
